600285 羚锐制药
2024/09 - 九个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入2,759,11610.07%3,311,4733,001,8622,693,5112,331,577
减:营业总成本2,132,9567.28%2,683,3042,584,4172,296,6341,997,801
    其中:营业成本689,7158.44%884,387832,114692,993538,403
               财务费用(13,194)-46.05%(35,120)(26,588)(10,334)(15,290)
               资产减值损失(409)108.57%(2,873)(171)(8,775)(32,028)
公允价值变动收益(3,646)-6,309.98%1215,92646(52)
投资收益29,543174.13%20,15458,65530,55541,208
    其中:对联营企业和合营企业的投资收益1,889-932.40%(385)43,35018,52233,230
营业利润662,67722.92%656,307517,121435,012367,092
利润总额665,10523.65%653,044517,035413,351364,201
减:所得税费用91,19727.21%84,92851,73050,85239,819
净利润573,90823.11%568,116465,305362,500324,382
减:非控股权益35790.36%60957(1,107)
股东净利润573,87323.10%568,109465,305361,543325,489

市场价值指针
每股收益 (元) *1.02423.37%1.0120.8360.6500.573
每股派息 (元) *----0.8000.6000.5000.400
每股净资产 (元) *5.1036.74%4.9214.4954.0144.073
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容